Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Gastric Cancer

Gastric Cancer

46 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Gastric Cancer

191 trials tracked for Gastric Cancer: 32 in phase 3 or 4 and 19 with published results. The most-cited published study has 1127 citations.

191Trials tracked
32Phase 3 & 4
0Recruiting
19With published results
Phase distribution
Phase 4 2 Phase 3 30 Phase 2 121 Phase 1 15 Other / NA 23
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,127 cited
  2. Phase 3 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Completed · 689 cited
  3. Phase 3 Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Completed · 511 cited
  4. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 501 cited
  5. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed · 490 cited
  6. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Completed · 388 cited
Show 44 more trials
  1. Phase 3 Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer Completed · 359 cited
  2. Phase 3 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Completed · 297 cited
  3. Phase 3 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed · 289 cited
  4. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 252 cited
  5. Phase 3 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Completed · 230 cited
  6. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 133 cited
  7. Phase 3 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Completed · 98 cited
  8. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 94 cited
  9. Phase 3 Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer Completed · 80 cited
  10. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study Completed · 55 cited
  11. Phase 3 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed · 9 cited
  12. Phase 3 Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient Completed · 8 cited
  13. Phase 3 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed · 3 cited
  14. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  15. Phase 3 Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Completed
  16. Phase 3 A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer Completed
  17. Phase 3 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Completed
  18. Phase 3 A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer Completed
  19. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension Completed
  20. Phase 3 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed
  21. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed
  22. Phase 3 A Safety and Efficacy Study in Patients With Gastric Cancer Completed
  23. Phase 3 ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer Completed
  24. Phase 3 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed
  25. Phase 3 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial Completed
  26. Phase 3 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed
  27. Phase 2 Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours Completed
  28. Phase 2 Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients Completed
  29. Phase 2 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer Completed
  30. Phase 2 Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Completed
  31. Phase 2 RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment Completed
  32. Phase 2 Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) Completed
  33. Phase 2 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed
  34. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  35. Phase 2 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer Completed
  36. Phase 2 Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer Completed
  37. Phase 2 A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. Completed
  38. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  39. Phase 2 IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Completed
  40. Phase 2 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Completed
  41. Phase 2 Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Completed
  42. Phase 2 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  43. Phase 2 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma Completed
  44. Phase 2 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed

Showing the 50 most-cited and recently-updated of 191 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Gastric Cancer: what the trials found

Pembrolizumab has demonstrated significant improvements in overall survival (OS) across multiple cohorts. In one study, OS was significantly improved in all participants (12.9 vs 11.5, p<0.0001), with even greater gains in patients with PD-L1 CPS ≥10 (15.7 vs 11.8, p<0.0001) 6. Another trial showed significant OS benefits for all participants (8.4 vs 5.6, p=0.0015), with specific benefits noted for patients with PD-L1 CPS ≥10 (12.0 vs 5.3, p=0.0008) 19. Additionally, pembrolizumab combined with XP/FP showed a statistically significant improvement in event-free survival (EFS) (44.4% vs 25.7%, p=0.01501) and a significantly higher pathological complete response (pathCR) rate (13.4% vs 2.0%, p<0.00001) 10.

Other immunotherapies and combinations have shown varying results. Nivolumab plus chemotherapy significantly improved both OS (14.39 vs 11.10, p<0.0001) and progression-free survival (PFS) (7.69 vs 6.05, p<0.0001) in patients with PD-L1 CPS ≥5 14. Tislelizumab showed significant improvements in OS for both PD-L1 positive participants (17.2 vs 12.6, p=0.0056) and the intent-to-treat population (15.0 vs 12.9, p=0.0011) 20. TAS-118 plus Oxaliplatin also demonstrated significant improvements in OS (16.0 vs 15.1, p=0.039), PFS (7.1 vs 6.4, p=0.0045), and time to treatment failure (6.1 vs 5.3, p=0.011) 18.

In contrast, some agents did not reach statistical significance in primary endpoints. TAS-102 showed a significant improvement in OS (5.7 vs 3.6, p=0.0003) 7, while Avelumab did not show significant improvements in OS (p=0.1779) 15 or in OS, PFS, or ORR (p>0.05) 8. Other trials, such as those involving 5-Fluorouracil 9, Olaparib 12, and Ramucirumab 13, provided data on response rates and survival but did not reach statistical significance for primary survival endpoints in the reported data.

recent": ["Perioperative treatment is currently being evaluated in a Phase 2 trial 1.", "Trastuzumab BS is under investigation in a Phase 1/2 trial 2."],

For the clinician treating this condition

  • Pembrolizumab is associated with significant improvements in OS and EFS, with notable benefits in patients with high PD-L1 expression [6, 10, 19].
  • Nivolumab plus chemotherapy and Tislelizumab have demonstrated statistically significant improvements in overall survival [14, 20].
  • TAS-118 plus Oxaliplatin showed significant improvements in OS, PFS, and time to treatment failure 18.
  • Avelumab did not demonstrate statistically significant improvements in OS or other primary endpoints in the reported trials [8, 15].

AI synthesis of 14 cited trials, updated Oct 9, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Neoadjuvant apatinib-based regimens achieve 93% R0 resection rate in resectable gastric and esophageal junction cancers
Oncology Meta-analysis
Neoadjuvant apatinib-based regimens achieve 93% R0 resection rate in resectable gastric and esophageal junction cancers Apatinib shows promise for patients with gastric and esophageal cancer
This single-arm meta-analysis of 975 patients evaluated neoadjuvant apatinib-based regimens for resectable gastric and gastroesophageal junc…
A new look at treatment data shows apatinib may help shrink tumors before surgery for patients with gastric and esophageal junction cancers.
Frontiers Oct 21, 2026
Older adults with gastric cancer achieve comparable survival despite higher toxicity and treatment modifications
Oncology RCT
Older adults with gastric cancer achieve comparable survival despite higher toxicity and treatment modifications Older adults with gastric cancer show similar survival to younger patients
This secondary analysis of a Phase III trial involved 574 patients with resectable gastric or gastro-esophageal junction adenocarcinoma. Old…
Older adults with gastric cancer can achieve similar survival rates to younger patients, even though they may face more treatment side effec…
Oct 10, 2026
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers
Gastroenterology Sys. Review
Fungal dysbiosis is associated with altered community structures and immune remodeling in several gastrointestinal cancers Fungi may play a role in several types of cancer
This narrative review synthesizes evidence regarding fungal dysbiosis in colorectal cancer, gastric cancer, and pancreatic ductal adenocarci…
New research explores how fungal imbalances in the body might link to colorectal, gastric, and pancreatic cancers.
Frontiers Oct 8, 2026
MOL-led WeChat and face-to-face intervention targets 30-day treatment in upper GI cancer
Oncology RCT
MOL-led WeChat and face-to-face intervention targets 30-day treatment in upper GI cancer New Management Plan Aims to Speed Up Cancer Treatment
This cluster randomised controlled trial protocol will test whether a MOL-led management intervention using WeChat-based health education an…
A new trial plans to use WeChat and face-to-face talks to help patients with upper gastrointestinal cancer start treatment faster.
Oct 1, 2026
AI tongue image analysis shows variable accuracy for gastric cancer screening
Gastroenterology Meta-analysis
AI tongue image analysis shows variable accuracy for gastric cancer screening AI Tongue Image Analysis Shows Potential for Gastric Cancer Screening
This systematic review of 9 studies examines AI-based tongue image analysis for gastric cancer and precancerous lesions. Internally validate…
Artificial intelligence may help identify gastric cancer and precancerous lesions through tongue images, offering a potential new non-invasi…
Frontiers Sep 29, 2026
Trastuzumab and tislelizumab show lower probability of health-related quality of life deterioration in gastric cancer
Oncology Meta-analysis
Trastuzumab and tislelizumab show lower probability of health-related quality of life deterioration in gastric cancer Trastuzumab and Tislelizumab May Improve Quality of Life in Gastric Cancer
This network meta-analysis of over 8000 patients evaluated first-line systemic therapies for unresectable advanced gastric cancer. The analy…
New analysis suggests that trastuzumab and tislelizumab may help patients with advanced gastric cancer maintain a better quality of life dur…
Frontiers Sep 28, 2026
Robotic gastrectomy shows no significant difference compared to laparoscopic gastrectomy for East Asian patients
Oncology Meta-analysis
Robotic gastrectomy shows no significant difference compared to laparoscopic gastrectomy for East Asian patients Robotic Surgery Shows No Difference from Laparoscopic Gastrectomy
This meta-analysis of 1,695 to 1,858 patients found no significant differences between robotic and laparoscopic gastrectomy for overall comp…
A review of surgical techniques for gastric cancer shows that robotic surgery does not change outcomes compared to laparoscopic methods.
Sep 26, 2026
Thymosin alpha1 plus chemotherapy improves response rates and immune markers in gastric cancer
Allergy & Immunology Meta-analysis
Thymosin alpha1 plus chemotherapy improves response rates and immune markers in gastric cancer Thymosin alpha1 combined with chemotherapy shows promise for gastric cancer
This meta-analysis of 1,704 patients found that thymosin alpha1 combined with chemotherapy improved objective response rates (RR = 1.39) and…
Adding thymosin alpha1 to chemotherapy may improve immune response and quality of life for patients with gastric cancer, according to a meta…
Frontiers Sep 18, 2026
Electrical Acupoint Stimulation May Speed Gut Recovery After Gastric Cancer Surgery
Drug Pipeline Meta-analysis
Electrical Acupoint Stimulation May Speed Gut Recovery After Gastric Cancer Surgery Electrical Acupoint Stimulation May Speed Recovery After Gastric Surgery
In a meta-analysis of 1,357 gastrectomy patients, electrical acupoint stimulation shortened time to flatus, defecation, and liquid intake, b…
Electrical acupoint stimulation may help patients pass gas and start drinking liquids sooner after surgery for gastric cancer.
Frontiers Sep 18, 2026
Autoimmune gastritis and pernicious anemia are associated with increased risks of gastric neoplasms
Oncology Meta-analysis
Autoimmune gastritis and pernicious anemia are associated with increased risks of gastric neoplasms Autoimmune gastritis and pernicious anemia linked to higher cancer risk
This meta-analysis evaluates the risk of gastric neoplasms in patients with autoimmune gastritis (AIG) and pernicious anemia (PA). The analy…
People with autoimmune gastritis or pernicious anemia face higher risks of certain stomach tumors and precancerous changes.
Sep 16, 2026
Multifactorial mechanisms including drug efflux and metabolic reprogramming drive paclitaxel resistance in several solid tumors
Drug Pipeline Sys. Review
Multifactorial mechanisms including drug efflux and metabolic reprogramming drive paclitaxel resistance in several solid tumors New research identifies why some cancers resist paclitaxel treatment
This systematic review synthesizes the biological mechanisms underlying paclitaxel resistance in ovarian, breast, non-small cell lung, and g…
Cancer cells can find ways to survive paclitaxel treatment through several complex biological changes, but new strategies are being explored…
Frontiers Sep 15, 2026
Antigen delivery and immune programming are the primary hurdles for H. pylori vaccine development
Infectious Disease Sys. Review
Antigen delivery and immune programming are the primary hurdles for H. pylori vaccine development Vaccine Development Faces Challenges for H. pylori Infections
This narrative review examines the current landscape of H. pylori vaccine development for conditions like gastritis and gastric cancer. The …
New research identifies why H. pylori vaccines have struggled to move from laboratory success to clinical protection for patients with stoma…
Frontiers Sep 15, 2026

Questions about Gastric Cancer

Does CIK/DC-CIK cell therapy improve survival rates for gastric cancer?

Yes, CIK/DC-CIK cell therapy plus chemotherapy improves overall survival and disease-free survival in gastric cancer patients compared to chemotherapy alone.

Full answer →
Does EGCG have therapeutic effects on digestive system diseases like gastric cancer?

Yes, EGCG shows therapeutic effects against gastric cancer in lab and animal studies by inhibiting cell growth, inducing apoptosis, and altering immune signals, but human trials are lacking.

Full answer →
Can machine learning predict anastomotic leaks in gastric cancer patients?

Yes, machine learning models can predict anastomotic leaks in gastric cancer patients with good accuracy, especially when using postoperative indicators and immunonutritional indices.

Full answer →
Does enteral immunonutrition reduce infection risks after gastric cancer surgery?

Yes, enteral immunonutrition (EIN) reduces infection risks after gastric cancer surgery, with a 52% lower odds of infectious complications compared to standard enteral nutrition, especially when given for 7–10 days perioperatively.

Full answer →

All Gastric Cancer Articles